Immuron North American Travelan Sales Up 95%, Global Sales Up 60%

Key Highlights:

• North American sales up by 95% YoY in Q3 FY20
• Immuron achieved 60% YoY growth in worldwide product sales in Q3 FY20.
• YTD March 31, FY20 worldwide sales reached AU $2.67M, increasing 57% YoY.
• In Australia, Q3 FY20 gross sales grew by 35% YoY to $475K.
• In the USA, Q3 FY20 gross sales increased by 50% YoY to AU $412K.
• In Canada, Q3 FY20 sales reached $96K.

MELBOURNE, Australia, April 20, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases, today announced the sales results of its commercially available and over-the-counter gastrointestinal and digestive health immune supplement Travelan for the third quarter of the fiscal year 2020 ending on March 31, 2020.

North American Travelan sales were up by 95% and worldwide product sales grew by 60% YoY in the third quarter of FY20, reaching AU $983K* compared to AU $616K in Q3 FY19. YTD March 31 worldwide sales reached AU $2.67M* marking a healthy 57% increase on the same time last year.

In Australia, Travelan sales increased to AU $475K* in Q3 FY20, representing a 35% increase over Q3 FY19 (AU $350K). Co-operative marketing initiatives with Pharmacies, including a Chemist Warehouse TV advertisement in December 2019 contributed to this growth. YTD March 31 sales in Australia reached AU $1.43M*, 35% higher than the same time last year.

In the US, Travelan sales continued their upward trajectory growing by 50% YoY to AU $412K* for Q3 2020. YTD March 31 US Sales (AU $926K*) were 46% higher than the same time last year. This growth was attributable to increasing sales in both Passport Health Travel Clinics and on the Amazon e-commerce channel. A consumer awareness campaign was launched in the USA in mid-February 2020 which generated valuable publicity for Travelan through a combination of earned media in digital news publications and through Travel Influencer channels. The campaign was cut short due to the impact that the COVID-19 pandemic had on international travel in late March.

In Canada, Travelan sales reached $96K* in Q3 FY20 with Loblaws commencing distribution and Shoppers Drug Mart increasing scan sales through co-operative marketing initiatives at store level. YTD March 31 Canadian sales were $313K* as brand awareness starts to build in this market.

In mid to late March 2020, the COVID-19 pandemic resulted in international travel restrictions being enacted in all markets in which Travelan is sold. It is anticipated these events will impact on Travelan sales in Q4 of FY20. The Company will look to increase overall revenues to help mitigate the anticipated decrease in Travelan sales – due to decreased travel – by promoting Travelan and Travelan's sister product, Protectyn, for their gut health benefits. The market effort will focus on the benefits that Travelan offers when it comes to maintaining digestive health. It is noteworthy that when people stay at home to self-isolate, they sometimes make poor dietary choices such as eating takeaway food that has been transported in uncontrolled temperatures or that has been poorly prepared, or which contains unhealthy ingredients. In addition, stress, changing routines and weakened immunity can also lead to digestion issues. Travelan helps to maintain the delicate balance of the gut microbiota by eliminating invading pathogens, whether you are travelling or self-isolating at home.